We would like to congratulate the winners of this year’s Investigator Award. The chosen winners presented their work at the EAN Virtual Congress in this May. The Investigator Award consists of a free registration to the 7th EAN Congress in Vienna 2021 and an award certificate.
Please find below the list of winners and their presentation titles:
Youssuf Saleh, Oxford, UNITED KINGDOM
O2024 Distinct white matter tract changes associated with apathy in cereberovascular small vessel disease.
Sean Apap Mangion, London, UNITED KINGDOM
O4013 Real world clinical features and management of neurotoxicity in CD19 targeted chimeric antigen receptor (CAR) T-cell therapy for high grade lymphoma with off-label use of anakinra
Francesca Fumagalli, Milan, ITALY
O4014 Effects of lentiviral (LV) hematopoietic stem and progenitor cell gene therapy (HSPC-GT) on central and peripheral demyelination and brain atrophy in late-infantile metachromatic leukodystrophy (LI-MLD)
Marco Pasi, Lille, FRANCE
O1030 Long-term functional decline in spontaneous intracerebral haemorrhage survivors
Linnéa Grindegård, Lund, SWEDEN
O2044 EEG background patterns correlate with serum neurofilament light after cardiac arrest
Alvaro Cobo-Calvo, Barcelona, SPAIN
O3024 Comparison of clinical characterization, risk of relapses and antibody dynamics between children and adults with MOGAD
Valeria Sansone, Milan, ITALY
O1012 Exploring Possible Predictors of Clinical Outcomes Following Nusinersen Treatment of Spinal Muscular Atrophy (SMA): Interim Results from the Phase 2 NURTURE Study
Maria Nolano, Arienzo, ITALY
O2017 Small fiber pathology in patients with Progressive Supranuclear Palsy
Maria Assunta Rocca, Milan, ITALY
O4012 Artificial Intelligence Applied on Conventional Magnetic Resonance Images Improves the Correct Diagnosis of CNS Diseases Mimicking Multiple Sclerosis
Markus Kneihsl, Graz, AUSTRIA
O1029 Intracranial pulsatility index on transcranial Doppler sonography: a marker of microangiopathic white matter hyperintensities?
Werner Poewe, Innsbruck, AUSTRIA
O3011 First results for The BeyoND Study: A phase 2b, international, open-label study evaluating long-term safety of ND0612 in patients with Parkinson’s disease experiencing motor complications
Elisabeth Hens, Antwerpen, BELGIUM
O3033 Alzheimer’s disease and cerebral amyloid angiopathy were associated with ABCA7 PTC mutation carriers in a large Belgian AD cohort
Francesca Baschieri, Bologna, ITALY
O2015 Validation of the new index of baroreflex function to identify neurogenic orthostatic hypotension
Marco Pasi, Lille, FRANCE
EPR2033Predictors of long-term mortality in spontaneous intracerebral haemorrhage survivors.
Raili Kauppinen, Helsinki, FINLAND
O4015 Reduction in Pain During and Between Attacks in Patients with Acute Hepatic Porphyria Treated with Givosiran: A Post-Hoc Analysis of the Phase 3 ENVISION Study
Horacio Kaufmann, New York, UNITED STATES OF AMERICA
O2019 Open-Label Phase 2 Study to Explore Durability of Effect and Safety of Once-Daily Oral Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, for Symptomatic Treatment of Neurogenic Orthostatic Hypotension in Subjects With Synucleinopathies
Matthias Amprosi, Innsbruck, AUSTRIA
O1021 Clinical and genetic findings in a multigenerational Austrian family harbouring a SCA40 mutation
Ermelinda De Meo, Milan, ITALY
O3032 Defining cognitive phenotypes of multiple sclerosis patients
João Leote, Almada, PORTUGAL
O2022 Accelerometer speech recording: technical aspects, reliability, clinical and intraoperative utility
Elena Abati, Milan, ITALY
O1013 Knockdown and Replacement of MFN2: a Gene Therapy to treat Dominantly Inherited Peripheral Neuropathy CMT2A
